NANEXA Nanexa AB (publ)
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Nanexa (STO: NANEXA)
›
Nanexa (STO: NANEXA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 9.950 SEK on 19 November 2026, up 503.8% over 52 weeks. Its 52-week range is 1.612 SEK to 15.50 SEK: the price is 35.8% below the high and 517.2% above the low.
At a market capitalisation of 1.94B SEK, it trades at 12.8 times trailing earnings and 45.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 48% for NANEXA.
Nanexa reports return on equity of -11.2% and an operating margin of 56.3%.
It holds more cash than debt, a net cash position of 43.32M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.